卡培他滨联合奥沙利铂治疗37例进展期胃癌临床研究  

Clinical Study on Advanced Gastric Cancer Treated by Capecitabin Combined with Oxaliplatin

作　　者：谢明瑞 牛建生[1] 师福香 

机构地区：[1]陕西省榆林市第二医院肿瘤内科,陕西榆林719000

出　　处：《医学综述》2011年第20期3190-3191,共2页Medical Recapitulate

摘　　要：目的探讨卡培他滨联合奥沙利铂治疗进展期胃癌的有效性和可行性。方法 2004年1月至2010年1月我院以卡培他滨联合奥沙利铂治疗37例进展期胃癌患者,分析临床疗效及不良反应情况。结果所有病例中完全缓解(CR)率为8.11%,总有效率(RR)率为54.05%,临床受益率为86.49%;出现了以血液系统病变为主并伴消化道反应、神经系统毒性和手足综合征的不良反应。结论以手术治疗为主合并新辅助化疗技术治疗进展期胃癌的临床疗效较好,如何选择恰当的化疗方案和给药方式是减少不良反应的关键。Objective To investigate the effectivity and feasibility of capecitabine and oxaliplatin treating on the advanced gastric cancer.Methods Retrospective studies of the clinical data of 37 cases diagnosed of advanced gastric cancer were done,including the clinical effect and adverse effects.Results The rates of complete remission（CR）,response rate（RR）and clinical benefit were 8.11%,54.05%,86.49%,respectively;the adverse effects were mainly characterized by the blood system diseases associated with gastrointestinal reactions,the nervous system toxicity and hand-foot syndrome.Conclusion The treatment of surgical operation associated with neoadjuvant chemotherapy on advanced gastric cancer was accepted by the patient better,and it is important to choose the appropriate chemotherapy regimens and delivery methods to reduce the adverse effects.

关 键 词：进展期胃癌 卡培他滨 奥沙利铂 临床研究 

分 类 号：R735.2[医药卫生—肿瘤]